| gap-debate-20260410- | What determines whether TREM2 activation enhances or reduces tau pathology in di | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do thalamocortical synchrony deficits relate to hippocampal circuit dysfunct | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do NMDA receptor-mediated circuit dysfunctions operate independently of spine lo | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroscience |
| gap-debate-20260410- | What are the temporal dynamics and regional heterogeneity of interneuron impairm | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Are interneuron oscillation deficits compensatory responses or primary pathologi | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do individual differences in microglial activation affect therapeutic respon | open | 0.75 | 0.00 | 2026-04-10 | 0 | | precision-medicine |
| gap-debate-20260410- | Which TREM2 downstream pathways are disrupted by loss-of-function variants in AD | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Do A1/A2 astrocyte states represent real biology or oversimplified classificatio | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-debate-20260410- | Is myelin loss in AD causal or an adaptive response to neuronal damage? | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | How do NLRP3 inflammasome and mitophagy pathways mechanistically interact in mic | open | 0.73 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Can BBB-penetrant galectin-3 inhibitors achieve therapeutic CNS exposure without | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Which microglial subtypes (DAM vs inflammatory) predominate at different disease | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do galectin-3 and beneficial TREM2 ligands directly compete for binding sites on | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What are the genome-wide off-target mutation rates of prime editing in human neu | open | 0.70 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Do CRISPR-mediated epigenetic modifications persist long-term in post-mitotic ne | open | 0.75 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-debate-20260410- | Can microglia-specific AAV delivery be achieved with sufficient efficiency and s | open | 0.80 | 0.00 | 2026-04-10 | 0 | | gene-therapy |
| gap-debate-20260410- | What is the optimal temporal window for MSH3/PMS1 suppression to prevent CAG exp | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Which CXCL10 functions are neuroprotective versus neurotoxic in different brain | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | Do white matter changes precede or follow oligodendrocyte transcriptomic dysfunc | open | 0.80 | 0.00 | 2026-04-10 | 0 | | aging-neurobiology |
| gap-debate-20260410- | What is the therapeutic window for ferroptosis inhibition before iron homeostasi | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Does CXCL10 inhibition compromise CNS immune surveillance during chronic treatme | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | How do BBB-penetrant CXCR3 antagonists affect CNS immune surveillance versus pat | open | 0.75 | 0.00 | 2026-04-10 | 0 | | drug-development |
| gap-debate-20260410- | Which microglial polarization states are causally linked to oligodendrocyte rege | open | 0.79 | 0.00 | 2026-04-10 | 0 | | glial-biology |
| gap-debate-20260410- | What is the causal relationship between tau aggregation and cellular senescence | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Do CXCL10-recruited CD8+ T cells provide neuroprotection or cause damage in agin | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neuroimmunology |
| gap-debate-20260410- | Do white matter oligodendrocyte protection strategies prevent or merely delay ne | resolved | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What determines cell-type specificity of aging gene expression changes that pred | open | 0.75 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | Can selective cGAS-STING inhibition preserve beneficial microglial functions whi | open | 0.78 | 0.00 | 2026-04-10 | 0 | | immunology |
| gap-debate-20260410- | Does AP1S1 downregulation cause neurodegeneration vulnerability or represent a p | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the tissue-specific safety thresholds for TFEB modulation in different | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuropharmacology |
| gap-debate-20260410- | Can TFEB-independent autophagy pathways bypass lysosomal dysfunction in neurodeg | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | cell-biology |
| gap-debate-20260410- | Does TFEB dysfunction causally drive neurodegeneration or represent compensatory | partially_addressed | 0.95 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What validated biomarkers can determine optimal TFEB activity windows during dis | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What are the safety thresholds for ketone-induced disruption of astrocytic gluco | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurotoxicology |
| gap-debate-20260410- | Can intermittent ketogenic pulses create lasting epigenetic neuroprotection with | open | 0.80 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-debate-20260410- | Does OXCT1 expression follow circadian rhythms that affect ketone utilization ef | open | 0.75 | 0.00 | 2026-04-10 | 0 | | chronobiology |
| gap-debate-20260410- | What is the optimal ketone dosing threshold to avoid metabolic steal syndrome wh | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurometabolism |
| gap-debate-20260410- | How do compensatory mechanisms respond to cell-type specific gene silencing in n | open | 0.70 | 0.00 | 2026-04-10 | 0 | | molecular-biology |
| gap-debate-20260410- | What are the context-dependent protective vs harmful roles of APOE4 in different | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | Can lipid nanoparticles achieve true astrocyte-selective delivery in the CNS? | open | 0.80 | 0.00 | 2026-04-10 | 0 | | drug-delivery |
| gap-debate-20260410- | Which neural cell types exhibit the most pronounced gene expression alterations | partially_addressed | 0.90 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-debate-20260410- | What epigenetic mechanisms establish and maintain pathological metabolic memory | open | 0.71 | 0.00 | 2026-04-10 | 0 | | epigenetics |
| gap-debate-20260410- | How do cell-type-specific metabolic reprogramming mechanisms differ between astr | open | 0.75 | 0.00 | 2026-04-10 | 0 | | cellular-metabolism |
| gap-debate-20260410- | Is the metabolic shift from ketogenesis to glycolysis in astrocytes adaptive or | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurobiology |
| gap-debate-20260410- | What are the precise temporal dynamics of astrocyte ketone production decline du | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the tissue-specific role of EMP1 in ER stress regulation across | open | 0.77 | 0.00 | 2026-04-10 | 0 | | cellular-stress-response |
| gap-pubmed-20260410- | How does dihydroceramide accumulation specifically induce protein aggregation in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | protein-aggregation |
| gap-pubmed-20260410- | What are the downstream molecular mechanisms by which saturated VLC ceramides dr | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does IL-10 deficiency mechanistically link decreased mono-unsaturated fatty | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |